Failed experiment by Cambridge scientists leads to surprise drug development breakthrough
St. John's College, University of CambridgePeer-Reviewed Publication
Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals – a discovery that could accelerate and improve how medicines are designed and made.
Published today (Thursday 12 March) in Nature Synthesis, the study introduces what the team calls an “anti-Friedel–Crafts” reaction. A classic Friedel–Crafts reaction uses strong chemicals or metal catalysts under harsh experimental conditions. This means the reaction can only happen in the early stages of drug manufacturing, and is followed by many additional chemical steps to produce the final drug.
The new Cambridge approach reverses that pattern, allowing scientists to modify drug molecules at the final stages of production.
Rather than relying on heavy metal catalysts, the chemistry is powered by an LED lamp at ambient temperature. When activated, it triggers a self-sustaining chain process that forges new carbon–carbon bonds under mild conditions and without toxic or expensive chemicals.
In practical terms, this means chemists can make targeted changes late in the development of a new or existing drug rather than dismantling and rebuilding complex molecules from scratch – a process that can otherwise take months.
“We’ve found a new way to make precise changes to complex drug molecules, particularly ones that have been exceptionally difficult to modify in the past,” said David Vahey, first author and a PhD researcher at St John’s College, Cambridge.
“Scientists can spend months rebuilding large parts of a molecule just to test one small change. Now, instead of doing a multistep process for hundreds of molecules, scientists can start with their hit and make small modifications later on.”
- Journal
- Nature Synthesis